CREATES Act will speed up generic access in USA, trade group says

22 June 2016

The US trade association representing pharmacy benefit managers has said that new bipartisan legislation will bring generic drugs to market sooner.

The Pharmaceutical Care Management Association (PCMA) has praised the Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act, which has been introduced by three US Senators with the aim of promoting competition and affordability in the prescription drug market place.

Key to this will be encouraging more development of generic and biosimilar drugs and reducing overall drug costs by preventing brand drug manufacturer abuses of risk evaluation and mitigation strategies (REMS) that block generic competition.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK